Literature DB >> 32508034

Predicted value of coagulation function for prognosis and admission time to negative RT-PCR detection in non-critical COVID-19 patients.

Zibo Meng1,2, Dianyun Ren3,4, Yun Liu1,2, Xiaoming Lu5, Wei Xiong1,2, Xin Jin3,4,5.   

Abstract

Entities:  

Year:  2020        PMID: 32508034      PMCID: PMC7300596          DOI: 10.1002/ctm2.42

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN: 2001-1326


× No keyword cloud information.
Since December 2019, coronavirus disease 2019 (COVID‐19) swept around the world and resulted in 2 463 153 confirmed cases with 172 260 deaths by April 22, 2020. Several studies had reported that severe patients showed higher levels of d‐dimer, prothrombin time (PT), and activated partial thromboplastin time (APTT). Alex et al suggested the use of thromboprophylaxis in COVID‐19 patients, particularly those with evidence of activation of the coagulation system on admission. However, the effective predictor of the interval between the admission time and negative RT‐PCR detection (ATN) is unknown. We conducted retrospective study between February 13, 2020 and March 13, 2020 in Cancer Center of Wuhan Union Hospital (Wuhan, China), which was designated hospital to centralized admission COVID‐19 patients since February 13, 2020, to reveal the potential role for coagulation parameters in COVID‐19 patients. The diagnosis was confirmed according to the diagnostic standards in the “Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019‐nCoV) Infection” by the National Health Commission of the People's Republic of China. Based on this, disease severity was divided into mild type (I, with mild clinical symptoms but without imaging features of COVID‐19 infection), common type (II, with clinical symptoms such as fever and/ or respiratory symptoms and with imaging features of COVID‐19 infection), and severe type (III, comply with any one of the followings: respiratory rate ≥ 30/min, Oxygen saturation ≤ 93%, PaO2/FiO2 ≤ 300 mm Hg, and/or focus of COVID‐19 infection progress rapidly(≥50%/24 h)), and critical type (IV, ICU patient). Clinical characteristics and lab test results, including coagulation tests data, and time to get the endpoint (negative RT‐PCR detection for twice, in minimum 24 h sampling interval) were obtained from electronic medical records using a standardized data collection form. All these data were checked and reviewed by independent and experienced doctors. Critical type patients were excluded from our current study based on our research purpose. Blood samples were collected within 24 h after admission to perform coagulation testing, including APTT, PT, d‐dimer, AT III, FDP, INR, FIB, and TT. The baseline clinical characteristics of non‐critical patients with COVID‐19 were shown in Table 1, and the coagulation results showed that the level of D‐dimer (1.42 ± 2.27) and fibrinogen (FIB, 4.36 ± 1.27) were higher in COVID‐19 patients compared with regular people, which indicated that the COVID‐19 patients were suffered from coagulation dysfunction.
TABLE 1

Univariate analysis of clinical characteristics of patients according to ATN (cutoff value = 26). Continuous variables are presented as mean ± SD

ParameterAll patientsPercentage (%)Normative valuesATN < 26ATN ≥ 26 P
No.1105258
Age, years62.3 ± 13.356.83 ± 14.3867.22 ± 10.06<.001
Sex.129
Male5146.432(61.5%)27(46.6%)
Female5953.620(38.5%)31(53.4%)
With underlying health conditions
Hypertension3330.0
Diabete1513.6
COPD32.7
Cancer43.6
APTT, s37.45 ± 4.6128‐43.5s36.94 ± 4.2038.50 ± 4.77.070
PT, s13.46 ± 0.9611‐16s13.21 ± 0.8413.69 ± 1.00.007
D‐dimer, mg/l FEU1.42 ± 2.27<0.5 mg/L FEU36.94 ± 4.2038.50 ± 4.77.070
AT III, %84.57 ± 15.2880‐120%13.21 ± 0.8413.69 ± 1.00.007
FDP, ug/ml5.12 ± 9.38<5ug/ml36.94 ± 4.2038.50 ± 4.77.070
INR1.05 ± 0.100.8‐1.3113.21 ± 0.8413.69 ± 1.00.007
FIB, g/l4.36 ± 1.272.0–4.0 g/l36.94 ± 4.2038.50 ± 4.77.070
TT, s17.57 ± 1.2814–21 s13.21 ± 0.8413.69 ± 1.00.007
Disease severity<.001
I1816.418(34.6%)0(0%)
II6256.428(53.8%)34(58.6%)
III3027.26(11.5%)24(41.4%)
ATN, days23.7 ± 5.419.15 ± 4.3627.81 ± 1.89<.001

Continuous variables are presented as mean ± SD. (COPD: Chronic Obstructive Pulmonary Disease; PT: prothrombin time; APTT: activated partial thromboplastin time; AT III: antithrombin Ⅲ; FDP: Fibrinogen degradation product; INR: International standard ratio; FIB: fibrinogen; TT: thrombin time; ATN: admission time to negative. Continuous variables were presented as means and standard deviations (mean  ±  SD) and categorical variables were presented as counts and percentages. Patient characteristics were compared using Student's t test for continuous variables. Pearson's chi‐square test or Fisher exact tests were conducted for categorical variables.)

Univariate analysis of clinical characteristics of patients according to ATN (cutoff value = 26). Continuous variables are presented as mean ± SD Continuous variables are presented as mean ± SD. (COPD: Chronic Obstructive Pulmonary Disease; PT: prothrombin time; APTT: activated partial thromboplastin time; AT III: antithrombin Ⅲ; FDP: Fibrinogen degradation product; INR: International standard ratio; FIB: fibrinogen; TT: thrombin time; ATN: admission time to negative. Continuous variables were presented as means and standard deviations (mean  ±  SD) and categorical variables were presented as counts and percentages. Patient characteristics were compared using Student's t test for continuous variables. Pearson's chi‐square test or Fisher exact tests were conducted for categorical variables.) Studies had shown that the disease severity and prognosis of COVID‐19 patients were significantly affected by multiple confounding factors, especially by age and coagulation function. , , Consistently, our result showed that the higher disease severity population had a higher proportion of patients with abnormal coagulation function, especially for AT III, d‐dimer, and FIB, which showed significant differences (P < .05, Figure 1A).
FIGURE 1

A, the proportion of patients with abnormal coagulation function test parameters in different disease severity groups. “*” represents P < .05. B, AUC of parameters to predict ATN for patients with COVID‐19. (AUC, area under curve; 95% CI, 95% confidence interval). C, ATN‐dependent ROC analysis for patients with COVID‐19

A, the proportion of patients with abnormal coagulation function test parameters in different disease severity groups. “*” represents P < .05. B, AUC of parameters to predict ATN for patients with COVID‐19. (AUC, area under curve; 95% CI, 95% confidence interval). C, ATN‐dependent ROC analysis for patients with COVID‐19 Ling et al, showed that the median time from the onset of symptoms to first negative RT‐PCR results for oropharyngeal swabs in convalescent patients was 9.5 (6.0‐11.0) days. Inconsistently, median time for ATN was 23.7 ± 5.4 days (Table 1), which may contribute to the older age for COVID‐19 patients in our study (62.3 years vs 44 years). More importantly, we set the negative RT‐PCR detection for two times as the observed outcome, which could avoid false negatives with maximum degree. Zhang et al. had respectively reported the prognostic value of D‐dimer on admission in COVID‐19 patients, but predicted value of D‐dimer level on ATN was still unclear. In this study, the COVID‐19 patients were divided into two groups and univariate analyze were conducted according to the median cutoff value of ATN = 26, and the result demonstrated that the coagulation function, especially D‐dimer, together with diagnosed age and disease severity were associated with ATN (Table 1). The area under the ROC (receiver operator characteristic) curve (AUC) showed that age, disease severity level, and D‐dimer level had the better predictive effect to ATN in COVID‐19 patients, the AUC were 0.719, 0.744, and 0.723, respectively (Figure 1B and C).

CONCLUSION

In conclusion, our study revealed the correlation between highly deviating of coagulation function and high disease severity, also poor prognosis. Importantly, the result proved the accurately predicted value of high D‐dimer levels to longer ATN in non‐critical COVID‐19 patients.
  6 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

3.  Hospital-based use of thromboprophylaxis in patients with COVID-19.

Authors:  Alex C Spyropoulos; Walter Ageno; Elliot S Barnathan
Journal:  Lancet       Date:  2020-04-21       Impact factor: 79.321

4.  Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.

Authors:  Yun Ling; Shui-Bao Xu; Yi-Xiao Lin; Di Tian; Zhao-Qin Zhu; Fa-Hui Dai; Fan Wu; Zhi-Gang Song; Wei Huang; Jun Chen; Bi-Jie Hu; Sheng Wang; En-Qiang Mao; Lei Zhu; Wen-Hong Zhang; Hong-Zhou Lu
Journal:  Chin Med J (Engl)       Date:  2020-05-05       Impact factor: 2.628

5.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

6.  D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19.

Authors:  Litao Zhang; Xinsheng Yan; Qingkun Fan; Haiyan Liu; Xintian Liu; Zejin Liu; Zhenlu Zhang
Journal:  J Thromb Haemost       Date:  2020-06       Impact factor: 16.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.